Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.
Minuesa, Gerard; Albanese, Steven K; Xie, Wei; Kazansky, Yaniv; Worroll, Daniel; Chow, Arthur; Schurer, Alexandra; Park, Sun-Mi; Rotsides, Christina Z; Taggart, James; Rizzi, Andrea; Naden, Levi N; Chou, Timothy; Gourkanti, Saroj; Cappel, Daniel; Passarelli, Maria C; Fairchild, Lauren; Adura, Carolina; Glickman, J Fraser; Schulman, Jessica; Famulare, Christopher; Patel, Minal; Eibl, Joseph K; Ross, Gregory M; Bhattacharya, Shibani; Tan, Derek S; Leslie, Christina S; Beuming, Thijs; Patel, Dinshaw J; Goldgur, Yehuda; Chodera, John D; Kharas, Michael G.
; 10(1): 2691, 2019 06 19.
Artigo em Inglês | MEDLINE | ID: mdl-31217428
Doubling Down on Mutant RAS Can MEK or Break Leukemia.
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.